Effective immunotherapy promotes the killing of cancer cells by cytotoxic T cells. This
requires not only that cancer-specific T cells be generated, but also that these T cells …

CD8+ T cells specific for cancer cells are detected within tumours. However, despite their
presence, tumours progress. The clinical success of immune checkpoint blockade and …

Cancer treatment by immune checkpoint blockade (ICB) can bring long-lasting clinical
benefits, but only a fraction of patients respond to treatment. To predict ICB response, we …

Nanoparticle-sensitized photoporation is an upcoming approach for the intracellular delivery
of biologics, combining high efficiency and throughput with excellent cell viability. However …

Melanoma, a skin cancer that develops from pigment cells, has been studied intensively,
particularly in terms of the immune response to tumours, and has been used as a model for …

Forward genetic screens are powerful tools for the discovery and functional annotation of
genetic elements. Recently, the RNA-guided CRISPR (clustered regularly interspaced short …

Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to
its success for hematological malignancies in clinical studies leading to the US Food and …

Human T cells are central effectors of immunity and cancer immunotherapy. CRISPR-based
functional studies in T cells could prioritize novel targets for drug development and improve …

Chimeric antigen receptor (CAR)-T cell-based immunotherapy for cancer and
immunological diseases has made great strides, but it still faces multiple hurdles. Finding …

Tumours progress despite being infiltrated by tumour-specific effector T cells. Tumours
contain areas of cellular necrosis, which are associated with poor survival in a variety of …